CML慢性期三氧化二砷联合高三尖杉酯碱治疗的临床探讨

The Clinic Study of Therapy in the Chronic Myelocytic Leukemia-Chronic Phase by As_2O_3 Combined with Homoharringtoninum

目的探讨三氧化二砷(AS2O3)联合高三尖杉酯碱治疗慢性粒细胞白血病(CML)慢性期的疗效和安全性。方法对7例CML慢性期患者采用AS2O3联合高三杉酯碱方案治疗。AS2O310mg/d,2～3周,高三尖杉酯碱3～4mg/d,1～2周。结果一个疗程后7例均获得临床缓解,其中4例获得完全血液学缓解,均为初治患者,3例获得部分缓解,其中2例初治、1例为复治患者。4例完全缓解的患者,又进行第2次巩固治疗,仍持续血液学完全缓解。不良反应主要为Ⅲ度骨髓抑制和轻度肝功能损害,没有明显的恶心、呕吐、腹泻和黏膜炎。结论AS2O3联合高三尖杉酯碱是CML慢性期治疗的安全有效方案。

Objective To study the effctiveness and safety of arsenic trioxide（As2O3 ） combined with Homoharringtoninum in the chronic myelocytic leukmia - chonic phase （ CML - CP）. Methods Seven patients were treated with As2O3 10mg per day for 2 - 3 week and with Homoharringtoninum 3 - 4mg per day for 1 - 2. Results All patients were clinic remission, of which there were 4 complete remission who were all initial therapy, and 3 partial remission,2 of who were initial therapy and 1 was resume threapy. 4 patients of CR were treated with second strengthen therapy and continued hematologic CR. The main side effects were grade 3 hematologic toxicity and light liver damage,and no significant nausea,emesis,diarrhea or mucositis. Conclusion As2O3 combined with Homoharringtonium in the C ML -CP is a safe and cffctive regimen.